Gout is a complex form of inflammatory arthritis characterized by recurrent attacks of a severe pain and swollen joints. Gout therapeutics market is rapidly growing due to factors such as growing incidence of gout, significant unmet needs, growing treatment awareness, and promising pipeline molecules. The incidence of gout varies widely around the globe, with developed countries generally having higher prevalence than developing countries due to genetic, dietary and environmental factors. Favorable reimbursement policies by government agencies and private organizations in developed countries, growing number of obese population and rising treatment compliance are another factors that fueling the market growth of gout therapeutics.
The report titled “Gout therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2021–2029” offers strategic insights into the overall gout therapeutics market along with the market size and estimates for the duration 2019 to 2029. The research study covers in-depth analysis of market segments based on drug class (non-steroidal anti-inflammatory drugs, colchicine, corticosteroids and uric acid lowering agents) and different geographical regions.
Market size and forecast for these regional and country level markets are presented in this study for the period 2019-2029. Market growth rates for the forecast period 2021-2029 are also included in this report, considering 2020 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global gout therapeutics market. Pipeline analysis of gout therapeutics and global epidemiology of gout has been included in the study. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global gout therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global gout therapeutics market. In-depth competitive environment analysis and historical years (2019) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global gout therapeutics market, offering market size and estimates for the period from 2019 to 2029, keeping in mind the above-mentioned factors.
Gout is a complex form of arthritis characterized by sudden, severe attacks of pain and tenderness in joints. The incidence of gout has increased to a great extent in the past two decades. According to the U.S. Centers for Disease Control and Prevention (CDC) gout affects approximately 4 percent of Americans. Therapeutics not only treat gout symptoms but also prevent future flares and reduce the risk of complications. Colchicine, corticosteroids and NSAIDs such as ibuprofen, naproxen, celecoxib, indomethacin etc. are recommended in treatment of acute gout attack. Currently, NSAIDs are dominating the gout therapeutics market due to its wide availability, lower price and ability to reduce gout pain and inflammation. Combination therapy of uric acid lowering agents is noticed to be widely administered, and it is estimated that it will show significant market growth during the forecast period due to faster onset of action with minimum the adverse effects. Duzallo (lesinurad and allopurinol), approved in 2021 is touted to be a promising drug for gout treatment and Ironwood expected to exceed total annual U.S. peak sales of $300 million. Presence of ideal pipeline molecules such as arhalofenate, bucillamine, levotofisopam, ulodesine, verinurad etc. would assist in achieving significant market growth during forecast period 2021-2029. Due to target specificity and efficacy, demand for biologics is expected to increase in market. At present, approved biologics such as Canakinumab and Krystexxa are driving the growth of gout therapeutics market globally.
The prevalence and incidence of gout varies widely around the globe, with developed countries generally having higher prevalence than developing countries due to genetic, dietary and environmental factors. However, the highest prevalence worldwide is reported in Taiwanese, with some estimates of more than 10%. It is studied that, in the base year 2020, North America dominated the gout therapeutics market. United States was largest revenue contributor due to the upsurge in funding by government agencies and private organizations in healthcare system, higher cost of therapeutics and large number of target population with high treatment awareness. According to the Centers for Disease Control and Prevention (CDC), more than 4 percent of population is affected with gout in United States. Expected launch of pipeline molecules such as arhalofenate, bucillamine, levotofisopam, ulodesine, verinurad etc. is expected to assist gout therapeutics market growth in North America. On the other hand, Asia Pacific is estimated to show the fastest market growth over the forecast years due to the rising number of affected population, growing investment of key players with the local manufacturers in the region, and rapidly improving healthcare infrastructure. Furthermore, changing lifestyle pattern, growing rates of smoking & alcohol consumption boost the gout therapeutics market over the forecast period 2021-2029.
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Gout Therapeutics market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Drug Class
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
